TSRL, INC.

Ann Arbor, MI · Medtech

Transdermal microneedle patch for delivery of zanamivir (antiviral drug) to treat influenza

Grants
$27M
30 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
8
0 granted · 8 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Broad Spectrum Antiviral Nucleoside Phosphonate Analogs$2,987,766
Federal grantDepartment of Health and Human Services · Phase I · Nucleoside Phosphonate Analogs for the Treatment of Adenoviral Infection$299,360
Federal grantDepartment of Health and Human Services · Phase II · Broad Spectrum Antiviral Nucleoside Phosphonate Analogs$990,162
Federal grantDepartment of Health and Human Services · Phase II · Broad Spectrum Antiviral Nucleoside Phosphonate Analogs$999,700
Federal grantDepartment of Health and Human Services · Phase I · Microneedle Delivery of Zanamivir for Treatment of Influenza Infections$572,526
Federal grantDepartment of Health and Human Services · Phase I · Cell-penetrating antimicrobial therapeutics for treatment of complicated skin and soft tissue infections$583,958
Federal grantDepartment of Health and Human Services · Phase II · Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections$1,000,000
Federal grantDepartment of Health and Human Services · Phase I · Microneedle Delivery of Zanamivir for Treatment of Influenza Infections$284,761
Federal grantDepartment of Health and Human Services · Phase I · Cell-penetrating antimicrobial therapeutics for treatment of complicated skin and soft tissue infections$300,000
Federal grantDepartment of Health and Human Services · Phase II · Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections$983,590
Federal grantDepartment of Health and Human Services · Phase I · A Novel Combination Therapy to Treat Biofilm-based Pneumonia Infections$299,733
Federal grantDepartment of Health and Human Services · Phase II · Microneedle Delivery of Zanamivir for Treatment of Influenza$998,654
Federal grantDepartment of Health and Human Services · Phase II · Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections$971,090
Federal grantDepartment of Health and Human Services · Phase I · A Novel Combination Therapy to Treat Biofilm-based Pneumonia Infections$270,047
Federal grantDepartment of Health and Human Services · Phase II · Microneedle Delivery of Zanamivir for Treatment of Influenza$971,504
Federal grantDepartment of Health and Human Services · Phase II · Microneedle Delivery of Zanamivir for Treatment of Influenza$952,176
Federal grantDepartment of Health and Human Services · Phase II · Development of Synthetic High-Density Lipoproteins for Treatment of Sepsis$1,632,248
Federal grantDepartment of Health and Human Services · Phase II · Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections$1,999,466
Federal grantDepartment of Health and Human Services · Phase I · Novel, Safe, Efficacious Heparin Reversal$394,392
Federal grantDepartment of Health and Human Services · Phase I · Microneedle Delivery of Trospium Chloride Optimized for Improved Tolerance and Patient Outcomes in Overactive Bladder Disease$299,620
Federal grantDepartment of Health and Human Services · Phase II · Development of Synthetic High-Density Lipoproteins for Treatment of Sepsis$643,779
Federal grantDepartment of Health and Human Services · Phase II · Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections$999,604
Federal grantDepartment of Health and Human Services · Phase II · Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.$998,521
Federal grantDepartment of Health and Human Services · Phase I · Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu$299,999
Federal grantDepartment of Health and Human Services · Phase II · Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.$997,670
Federal grantDepartment of Health and Human Services · Phase II · Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections$998,663
Federal grantDepartment of Health and Human Services · Phase II · Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu$999,746
Federal grantDepartment of Health and Human Services · Phase II · Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.$999,765
Federal grantDepartment of Health and Human Services · Phase II · Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu$999,975
Federal grantDepartment of Health and Human Services · Phase II · Microneedle delivery of Trospium Chloride optimized for improved tolerance and patient outcomes in overactive bladder disease$1,097,498
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1294PARATECHS CORP——
1295SCALAR MAGNETICS, LLC——
1296Vital Connect, Inc.—$83M
1297TSRL, INC.——
1298Activated Research Company, LLC——
1299Fractyl Health—$274M
1300CAMBIUM MEDICAL TECHNOLOGIES, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 8
  • Swellable Hydrogel Microneedles Backed By A Drug Reservoir Patchapplication
  • Swellable Hydrogel Microneedles Backed By A Drug Reservoir Patchapplication
  • Metabolically Stable Prodrugsapplication
  • Metabolically Stable Prodrugsapplication
  • Neuraminidase Inhibitorsapplication
  • Prodrugs Of Neuraminidase Inhibitorsapplication
  • Prodrugs Of Triciribine And Triciribine Phosphateapplication
  • Prodrug Compositionapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.